Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe
(2017) In Eurosurveillance 22(7). p.1-9- Abstract
- We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0–14, 15–64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65–79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5b462a95-4bb0-466c-9be4-4c4a63baf833
- author
- Kissling, Esther ; Rondy, Marc and I-MOVE/I-MOVE+ study team (incl. G.Gefenaite)
- contributor
- Gefenaite, Giedre
LU
- publishing date
- 2017-02-16
- type
- Contribution to journal
- publication status
- published
- in
- Eurosurveillance
- volume
- 22
- issue
- 7
- pages
- 1 - 9
- publisher
- European Centre for Disease Prevention and Control (ECDC)
- external identifiers
-
- scopus:85014105621
- ISSN
- 1560-7917
- DOI
- 10.2807/1560-7917.ES.2017.22.7.30464
- project
- Infectious diseases surveillance, vaccine effectiveness and determinants of acceptance
- language
- English
- LU publication?
- no
- id
- 5b462a95-4bb0-466c-9be4-4c4a63baf833
- date added to LUP
- 2023-02-02 10:45:42
- date last changed
- 2023-02-03 04:06:18
@article{5b462a95-4bb0-466c-9be4-4c4a63baf833, abstract = {{We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0–14, 15–64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65–79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).}}, author = {{Kissling, Esther and Rondy, Marc and I-MOVE/I-MOVE+ study team (incl. G.Gefenaite)}}, issn = {{1560-7917}}, language = {{eng}}, month = {{02}}, number = {{7}}, pages = {{1--9}}, publisher = {{European Centre for Disease Prevention and Control (ECDC)}}, series = {{Eurosurveillance}}, title = {{Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe}}, url = {{http://dx.doi.org/10.2807/1560-7917.ES.2017.22.7.30464}}, doi = {{10.2807/1560-7917.ES.2017.22.7.30464}}, volume = {{22}}, year = {{2017}}, }